Coya Therapeutics, Common Stock Investor Sentiment

COYA Stock   6.52  0.13  1.95%   
About 54% of Coya Therapeutics,'s investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Coya Therapeutics, Common suggests that some traders are interested. The current market sentiment, together with Coya Therapeutics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Coya Therapeutics, Common stock news signals to limit their universe of possible portfolio assets.
  

Coya Therapeutics, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Coya Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at investing.com         
Coya Therapeutics completes Phase 2 Alzheimers study
Investing News at Macroaxis
over six months ago at businesswire.com         
Coya Therapeutics Announces 5 Million Strategic Investment by the Alzheimers Drug Discovery Foundati...
businesswire News
over six months ago at finance.yahoo.com         
Coya Therapeutics Announces 5 Million Strategic Investment by the Alzheimers Drug Discovery Foundati...
Yahoo News
over six months ago at businesswire.com         
Coya Therapeutics Announces 5 Million Strategic Investment by the Alzheimers Drug Discovery Foundati...
businesswire News
over six months ago at businesswire.com         
Coya Therapeutics Announces 5 Million Strategic Investment by the Alzheimers Drug Discovery Foundati...
businesswire News
over six months ago at investing.com         
ADDF invests 5 million in Coya Therapeutics for FTD treatment
Investing News at Macroaxis
over six months ago at seekingalpha.com         
Coya Therapeutics reports 5M strategic investment by ADDF
seekingalpha News
over six months ago at www.macroaxis.com         
Acquisition by Weinand Dieter of 5000 shares of Coya Therapeutics at 7.41 subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
Coya Therapeutics, Inc.s largest shareholders are retail investors with 60 percent ownership, inside...
Yahoo News
over six months ago at investorplace.com         
COYA Stock Earnings Coya Therapeutics Misses EPS for Q1 2024
sbwire news
over six months ago at gurufocus.com         
Coya Therapeutics Reports First Quarter 2024 Financial Results
Gurufocus Stories at Macroaxis
over six months ago at seekingalpha.com         
Coya Therapeutics GAAP EPS of -0.35
seekingalpha News
over six months ago at businesswire.com         
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Res...
businesswire News
over six months ago at businesswire.com         
Disposition of 17557 shares by Villalobos Anabella of Coya Therapeutics at 1.09 subject to Rule 16b-...
businesswire News
over six months ago at news.google.com         
Coya Therapeutics Successful Annual Meeting and Growth Plans - TipRanks
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Coya Therapeutics, that are available to investors today. That information is available publicly through Coya media outlets and privately through word of mouth or via Coya internal channels. However, regardless of the origin, that massive amount of Coya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Coya Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coya Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coya Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coya Therapeutics, alpha.

Coya Therapeutics, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 115000 shares by Arun Swaminathan of Coya Therapeutics, at 4.05 subject to Rule 16b-3
09/10/2024
2
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of P...
09/16/2024
3
Coya Therapeutics Announces Closing of 10.0 Million Private Placement
10/23/2024
4
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Mo...
10/28/2024
5
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 in Alzheimers Disease Presented at the Clinical Tria...
10/29/2024
6
Acquisition by Arun Swaminathan of 5000 shares of Coya Therapeutics, at 7.3378 subject to Rule 16b-3
11/11/2024
7
Fred Grossman Purchases 2,710 Shares of Coya Therapeutics, Inc. Stock
11/13/2024
8
Coya therapeutics CFO David Snyder buys 12,934 in stock
11/14/2024
9
Coya Therapeutics, Inc. Short Interest Update
11/19/2024
10
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
11/25/2024

Complementary Tools for Coya Stock analysis

When running Coya Therapeutics,'s price analysis, check to measure Coya Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coya Therapeutics, is operating at the current time. Most of Coya Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Coya Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coya Therapeutics,'s price. Additionally, you may evaluate how the addition of Coya Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years